Cara Therapeutics reported $9.38M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
Assertio Holdings USD 9K 0 Dec/2023
Cara Therapeutics USD 9.38M 9.38M Sep/2025
Cassava Sciences USD 48.31M 0 Dec/2025
Chugai Pharma JPY 1.65B 50K Mar/2026
Cipla INR 807.78M 17K Mar/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1.02M Dec/2025
CSL USD 482.13M 93.87M Dec/2025
Grifols EUR 680.58M 846.11K Dec/2025
Halozyme Therapeutics USD 118.52M 741K Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Pacira USD 39.31M 1.81M Mar/2026
Pfizer USD 5.7B 13M Mar/2026
RedHill Biopharma USD 33.3B 20.4B Jun/2025
Supernus Pharmaceuticals USD 58.04M 582K Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024